The global scopolamine market size was estimated to be USD 414.8 million in 2023 and is expected to reach USD 772.9 million by 2034 with a CAGR of 5.91% during the forecast period 2024-2034. The increasing prevalence of motion sickness and PONV, growing popularity of transdermal patches, rising demand for minimally invasive surgeries, and increasing awareness of the benefits of scopolamine for IBS will drive market growth. Scopolamine is delivered simply and efficiently via transdermal patches. The patches are applied to the skin, where the medication is absorbed slowly into the bloodstream.
Motion sickness is a widespread illness that affects millions of individuals worldwide. It is produced by inner ear movement, which gives contradictory messages to the brain concerning the body's location and movement. This might cause nausea, vomiting, dizziness, and excessive perspiration. PONV is a disorder that affects patients who have had surgery. It is believed that the anesthetic and pain medication used during surgery, as well as the manipulation of the inner ear during surgery, are to blame. For instance, Defender Pharmaceuticals reported encouraging results in June 2023 from a significant Phase III clinical trial assessing the effectiveness of intranasal scopolamine in reducing nausea and vomiting brought on by motion.
By dosage form, the transdermal patches segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market and is predicted to grow with the increasing preference for non-invasive and patient-friendly drug delivery methods. The transdermal patches offer a convenient and sustained release of therapeutic agents, ensuring consistent medication absorption and minimizing the need for frequent dosing. For instance, Athira Pharma, Inc. used scopolamine in March 2022. Scopolamine is a novel small molecule that is being considered for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Parkinson's disease dementia. They also used ATH-1020, an oral small molecule candidate that penetrates the brain and is used to treat neuropsychiatric disorders. Additionally, the tablets segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing patient preference for oral medications, ease of administration, and ongoing advancements in tablet formulations, including extended-release and combination therapies.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the established infrastructure and expertise of hospital pharmacies make them pivotal hubs for ensuring the timely and accurate provision of prescribed therapeutics, facilitating coordinated patient care within the hospital setting. For instance, Novartis provides scopolamine as transdermal patches to treat nausea and vomiting. They introduced a scopolamine nasal spray into the US market in May 2023. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing consumer preference for digital health solutions, increased internet penetration, and the convenience of online platforms for purchasing Primary Biliary Cholangitis Therapeutics.
North American region is anticipated for the highest revenue share during the forecast period owing to the high prevalence of Primary Biliary Cholangitis (PBC) in the region, coupled with a well-established healthcare infrastructure and a robust pharmaceutical market. For instance, Mylan offers several forms of scopolamine, such as transdermal patches, pills, and injections. In May 2023, a scopolamine nasal spray was introduced in the United States. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of Primary Biliary Cholangitis (PBC), improving healthcare infrastructure, and a growing emphasis on personalized medicine in the Asia Pacific region.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Motion sickness is a widespread illness that affects millions of individuals worldwide. It is produced by inner ear movement, which gives contradictory messages to the brain concerning the body's location and movement. This might cause nausea, vomiting, dizziness, and excessive perspiration. PONV is a disorder that affects patients who have had surgery. It is believed that the anesthetic and pain medication used during surgery, as well as the manipulation of the inner ear during surgery, are to blame. For instance, Defender Pharmaceuticals reported encouraging results in June 2023 from a significant Phase III clinical trial assessing the effectiveness of intranasal scopolamine in reducing nausea and vomiting brought on by motion.
By dosage form, the transdermal patches segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market and is predicted to grow with the increasing preference for non-invasive and patient-friendly drug delivery methods. The transdermal patches offer a convenient and sustained release of therapeutic agents, ensuring consistent medication absorption and minimizing the need for frequent dosing. For instance, Athira Pharma, Inc. used scopolamine in March 2022. Scopolamine is a novel small molecule that is being considered for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Parkinson's disease dementia. They also used ATH-1020, an oral small molecule candidate that penetrates the brain and is used to treat neuropsychiatric disorders. Additionally, the tablets segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing patient preference for oral medications, ease of administration, and ongoing advancements in tablet formulations, including extended-release and combination therapies.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global Primary Biliary Cholangitis Therapeutics market in 2023 owing to the established infrastructure and expertise of hospital pharmacies make them pivotal hubs for ensuring the timely and accurate provision of prescribed therapeutics, facilitating coordinated patient care within the hospital setting. For instance, Novartis provides scopolamine as transdermal patches to treat nausea and vomiting. They introduced a scopolamine nasal spray into the US market in May 2023. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing consumer preference for digital health solutions, increased internet penetration, and the convenience of online platforms for purchasing Primary Biliary Cholangitis Therapeutics.
North American region is anticipated for the highest revenue share during the forecast period owing to the high prevalence of Primary Biliary Cholangitis (PBC) in the region, coupled with a well-established healthcare infrastructure and a robust pharmaceutical market. For instance, Mylan offers several forms of scopolamine, such as transdermal patches, pills, and injections. In May 2023, a scopolamine nasal spray was introduced in the United States. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of Primary Biliary Cholangitis (PBC), improving healthcare infrastructure, and a growing emphasis on personalized medicine in the Asia Pacific region.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Dosage Form, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Scopolamine Market Report 2023 - 2034
Scopolamine Market Analysis & Forecast by Type of Treatment 2023 - 2034 (Revenue USD Mn)
- Injectables
- Tablets
- Transdermal Patches
- Others
Scopolamine Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Scopolamine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Scopolamine Market: Type of Treatment Estimates & Trend Analysis
8. Scopolamine Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Scopolamine Market
11. Europe Global Scopolamine Market
12. Asia Pacific Global Scopolamine Market
13. Latin America Global Scopolamine Market
14. MEA Global Scopolamine Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Novartis AG
- Alkaloids Corporation
- Centroflora-CMS
- Fine Chemicals Corporation
- Phytex Australia
- Mylan N.V.
- Lannett Company Inc.
- Baxter International Inc.
- Perrigo Company plc
- Sandoz International GmbH (a division of Novartis)
- Alchem International Ltd.
- Acacia Pharma Group plc
- Alkaloida Chemical Company Zrt.
- Hi-Tech Pharmacal Co. Inc.
- CCM Duopharma Biotech Berhad
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 414.8 Million |
| Forecasted Market Value ( USD | $ 772.9 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
